Preliminary phase II study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Herbrecht, R
Borchmann, P
Wilhelm, M
Morschhauser, F
Hess, G
Kutz, K
Comis, S
Laffranchi, BL
Engert, A
机构：
[1] Hop Hautepierre, Dept Hematol & Oncol, Strasbourg, France
[2] Univ Cologne, Innere Med Klin 1, Cologne, Germany
[3] Klinikum Nurnberg N, Med Klin, Nurnberg, Germany
[4] Hop Huriez, Serv Pr Bauters, Lille, France
[5] Univ Mainz, Med Klin & Poliklin 3, D-6500 Mainz, Germany
[6] Accelpharm, Basel, Switzerland
[7] Cell Therapeut Inc, Clin Dept, Milan, Italy
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2489
引用
收藏
页码：682A / 683A
页数：2
相关论文
共 50 条
  • [31] Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin’s lymphoma
    R. I. Fisher
    Cancer Chemotherapy and Pharmacology, 1997, 40 : S42 - S46
  • [32] A gemcitabine, cisplatin and dexamethazone combination in patients with multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
    Emmanouilides, C
    Territo, M
    BLOOD, 1999, 94 (10) : 261B - 261B
  • [33] Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma
    Fisher, RI
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (Suppl 1) : S42 - S46
  • [34] Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma.
    Wilzig, Thomas E.
    Vose, Julie M.
    Kaplan, Henry P.
    Wolf, Jeffrey Lee
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Wiernik, Peter H.
    BLOOD, 2006, 108 (11) : 703A - 703A
  • [35] Phase-I study of BBR2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin lymphomas.
    Borchmann, P
    Knippertz, R
    Schnell, R
    Gamba, E
    Diehl, V
    Engert, A
    BLOOD, 1998, 92 (10) : 234B - 234B
  • [36] A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin's Lymphoma
    Cohen, Jonathon B.
    Switchenko, Jeffrey
    Koff, Jean L.
    Sinha, Rajni
    Kaufman, Jonathan L.
    Khoury, H. Jean
    Bumpers, Nassoma K.
    Colbert, Amanda
    Hutchison-Rzepka, Amanda A.
    Nastoupil, Loretta J.
    Heffner, Leonard T.
    Langston, Amelia
    Lechowicz, Mary Jo
    Lonial, Sagar
    Flowers, Christopher R.
    BLOOD, 2014, 124 (21)
  • [37] Treatment of elderly patients with aggressive non-Hodgkin's lymphoma.
    Paccalin, M
    Lacotte-Thierry, L
    Delwail, V
    REVUE DE MEDECINE INTERNE, 2002, 23 (07): : 632 - 637
  • [38] Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma
    Borchmann, P
    Schnell, R
    Knippertz, R
    Staak, JO
    Camboni, GM
    Bernareggi, A
    Hübel, K
    Staib, P
    Schulz, A
    Diehl, V
    Engert, A
    ANNALS OF ONCOLOGY, 2001, 12 (05) : 661 - 667
  • [39] Integrated efficacy results from two phase II studies utilizing sphingosomal vincristine for the treatment of multiply relapsed or refractory non-Hodgkin's lymphoma.
    Rodriguez, MA
    Sarris, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 594S - 594S
  • [40] A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma
    Tulpule, A
    Khan, AU
    Mohrbacher, AF
    Espina, BM
    Buchanan, L
    Berman, N
    Gorospe, G
    Boswell, WD
    Nathwani, BN
    Levine, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 604S - 604S
12345